What Taiho Pharmaceutical does

Taiho Pharmaceutical Co., Ltd. (大鵬薬品工業株式会社) is a Japan-headquartered pharmaceutical company founded in 1963 and operating today as a wholly-owned subsidiary of Otsuka Holdings Co., Ltd. The company runs two principal business segments. The first is prescription pharmaceuticals, anchored in oncology with 84.4% of FY2025 sales coming from cancer-related products and approximately 70% of pipeline dedicated to oncology indications, including major commercial products such as the TS-1/Teysuno oral fluoropyrimidine combination, Lonsurf (trifluridine/tipiracil) for metastatic colorectal cancer, Abraxane (nab-paclitaxel) for pancreatic and breast cancer, and INQOVI for acute myeloid leukemia. The second is a consumer healthcare (OTC) segment distributing branded Japanese products such as Tiovita Drink (~140 million bottles sold annually in FY2025), Solmack, Harncare, Pitas, and Zenol through pharmacy, drug store, and retail channels nationwide.

Taiho's underlying technology rests on two proprietary drug discovery platforms. The first is Cysteinomics (シスタイノミクス創薬), a 10+ year internally developed platform that selectively forms covalent bonds with cysteine amino acids in target proteins, enabling drug development against historically undruggable targets; the platform has produced approved agents in Japan, the U.S., and Europe. The second is AraLinQ™, a next-generation antibody-drug conjugate (ADC) platform acquired via the March 2025 purchase of Araris Biotech AG (a $400 million upfront deal) that features site-specific conjugation, defined binding sites, favorable physicochemical properties and blood stability, and the ability to load multiple payload types — already producing ARC-02, a CD79b-targeting ADC that entered Phase 1 trials in April 2026. R&D activity is supported by two main drug discovery centers in Tsukuba (Japan) and Zurich (Switzerland).

Taiho monetizes through three revenue streams: prescription drug sales to medical institutions in Japan (sales-led, MR-promoted), OTC consumer healthcare sales through retail pharmacy and drug-store channels with disclosed retail pricing typically ¥1,000–¥5,000 per unit, and licensing / co-development royalties and milestone payments from international partners including Cullinan Oncology/Therapeutics, Merck (via Astex), Arcus Biosciences, and others. The group's geographic footprint spans 16 countries with 21 overseas locations and a 60.2% overseas-sales ratio in FY2025; corporate-venture activity is conducted through Taiho Ventures, LLC (the largest CVC fund size among Japanese pharma CVCs, est. 2016) and Taiho Innovations (domestic CVC, est. 2019). FY2025 consolidated sales were ¥243 billion (~$2.43 billion) with 2,918 group employees and an R&D-to-sales ratio of 32.9%.

Name

Taiho Pharmaceutical

Legal name

Taiho Pharmaceutical Co., Ltd. (大鵬薬品工業株式会社)

Website

https://taiho.co.jp

Company type

Private

Founded year

1963

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Taiho Pharmaceutical is a Tokyo-based, Otsuka Holdings-owned pharmaceutical company that develops and markets oncology prescription drugs (84.4% of FY2025 sales) and Japanese consumer healthcare brands via proprietary Cysteinomics covalent-chemistry and AraLinQ ADC drug discovery platforms, generating ¥243 billion in FY2025 revenue.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Oncology pharmaceuticals
• Cancer therapeutics
• Consumer healthcare products
• Drug discovery platforms
• Prescription medications

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices15 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Prescription Pharmaceutical Products: Medical-use prescription drugs sold primarily in Japan, including anticancer agents (TS-1, LonSurf, Abraxane, Jevtana), antiemetics (Aloxi, Akaliz), and specialty drugs. Revenue generated through prescription sales to medical institutions.
2. Consumer Healthcare (OTC) Products: Over-the-counter products including Tiovita Drink series (vitamin supplements), Solmack gastrointestinal products, Harncare urinary products, Pitas throat products, Zenol pain relief products, and other health supplements sold through retail pharmacies and drug stores.
3. Licensing and Co-development Royalties: Revenue from licensing agreements, co-development partnerships, and milestone payments from international partners including Cullinan Oncology, Merck, and others for jointly developed oncology drugs.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Taiho Pharmaceutical develops, manufactures, and commercializes prescription pharmaceutical products, with a primary focus on oncology drugs for cancer treatment, alongside a portfolio of consumer healthcare (OTC) products. The company operates proprietary drug discovery platforms, including the Cysteinomix platform for cancer metabolism and the AraLinQ ADC platform for antibody-drug conjugates, to advance its pipeline of small molecules and biologics across global markets.

Product overview

Taiho Pharmaceutical operates two main business segments: Consumer Healthcare products (OTC medicines and health products) and Prescription Pharmaceuticals (primarily oncology-focused). Consumer Healthcare includes traditional medicines like Tiovita Drink (energy drink, ~140M bottles/year), Solmack (digestive liquid), Harncare (urinary issues), Pitas (throat troches), Zenol (topical analgesics), Bup-4 Lady (overactive bladder), and Efil (antibacterial spray). Prescription Pharmaceuticals focuses heavily on oncology with products like TS-1, Lonsurf, Abraxane, Yondelis, and pipeline candidates including Zipalertinib (EGFR inhibitor in FDA review), ARC-02 (ADC in Phase 1), and INQOVI. The company also operates advanced drug discovery platforms: Cysteinomix (coval binder technology with approved agents in JP/US/EU) and AraLinQ ADC technology (acquired 2025) for next-generation cancer therapies. R&D spending represents approximately 32.9% of sales with about 70% of pipeline in oncology.

Differentiator

Problem solved

Functional benefit

Brands

• Taiho Ventures: Strategic corporate venture capital arm of Taiho Pharmaceutical, established 2016, focusing on oncology biotech investments.
• Taiho Innovations
• Cysteinomix

Products and services

• Lonsurf (trifluridine/tipiracil)

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature2 records

Partnerships

Ten partnerships are on record, tiered strategic and core.

• BiocytogenstrategicTechnology or Integration · 30 March 2026Platform license agreement granting Taisho Pharmaceutical access to Biocytogen's proprietary RenNano® fully human heavy chain-only antibody discovery platform for internal R&D programs. Taisho will use RenNano® mice to generate and screen fully human HCAbs in vivo for antibody discovery research.
• Merck & Co. (development partner)coreStrategic or Co-development Partner · 7 January 2026Merck's KANDLELIT clinical development program for calderasib (MK-1084) includes Taiho Pharmaceutical as collaborator. Phase 3 KANDLELIT-007 trial evaluating calderasib with KEYTRUDA in first-line KRAS G12C-mutant NSCLC. Collaboration originally established with Astex Pharmaceuticals.
• Japanese Foundation for Cancer Research (JFCR)coreStrategic or Co-development Partner · 1 December 2025Joint research agreement with JFCR and NEC Corporation to develop new cancer vaccines using whole-genome information. Initiative aims to identify shared neoantigens for creating personalized cancer vaccines and demonstrate their therapeutic efficacy.
• NEC CorporationcoreTechnology or Integration · 1 December 2025Collaboration with JFCR and Taiho Pharmaceutical to develop cancer vaccines using whole-genome data and AI technology from NEC. Part of joint research agreement for neoantigen vaccine development.
• Arcus BiosciencescoreStrategic or Co-development Partner · 19 October 2025Taiho exercised option for exclusive license to casdatifan (HIF-2α inhibitor) in Japan and certain territories in Asia based on 2017 agreement. Casdatifan is currently in Phase 3 trial for kidney cancer, with Japan participation expected in 2026. Exercise includes payments and potential royalties.
• SyntheticGestaltstrategicTechnology or Integration · 4 June 2025Technical verification collaboration using SyntheticGestalt's SG4D10B molecular foundation AI model (world's largest molecule-specialized foundation model trained on 10 billion compound data points) to enhance Taiho's cysteinomics drug discovery platform. Aims to improve prediction accuracy for covalent drugs targeting historically undruggable proteins.
• Araris Biotech AGcoreStrategic or Co-development Partner · 1 March 2025Taiho Pharmaceutical acquired Araris Biotech AG in March 2025 to strengthen biologics and ADC research and development capabilities. Gained access to AraLinQ™ ADC technology platform for next-generation antibody-drug conjugate development. ARC-02 Phase 1 trial initiated based on this technology.
• Cullinan Oncology / Cullinan PearlcoreStrategic or Co-development Partner · 12 May 2022Agreement for Taiho to acquire Cullinan Pearl and co-develop Cullinan's EGFR inhibitor CLN-081/TAS6417 (zipalertinib) for NSCLC treatment. Deal included $275 million upfront payment with milestone payments and profit-sharing arrangements. Zipalertinib NDA accepted by FDA in April 2026.
• University of Texas MD Anderson Cancer CenterstrategicStrategic or Co-development Partner · 1 January 2020Collaborative research partnership established 2020 for comprehensive drug discovery research targeting difficult-to-treat cancers. Particularly focused on brain tumors and brain metastases using Taiho's brain-penetrating compound discovery platform combined with MD Anderson's external research expertise.
• Astex Pharmaceuticals / Merck & Co.coreStrategic or Co-development Partner · 1 January 2020Strategic collaboration in oncology established in 2020 involving Taiho Pharmaceutical, Astex Pharmaceuticals, and Merck & Co. for oncology drug discovery and development.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Daiichi Sankyo: Japanese pharmaceutical company with leading oncology franchise including the DXd antibody-drug conjugate platform (Enhertu, Datroway). Direct comparable in Japanese oncology pharma with overlapping ADC and targeted oncology development priorities.
• Chugai Pharmaceutical: Major Japanese oncology-focused pharmaceutical company (Roche subsidiary), with strong franchise in solid tumors and hematologic cancers. Highly comparable therapeutic focus and Japanese market footprint.
• Astellas Pharma: Japanese pharmaceutical company with concentrated oncology franchise (Xtandi, Vyloy, Padcev via Pfizer partnership). Comparable in shifting toward specialty/oncology focus and global development footprint.
• Ono Pharmaceutical: Japanese pharmaceutical company with oncology franchise including Opdivo (co-developed with BMS) and pipeline in solid tumors. Comparable mid-size Japanese oncology-focused pharma peer.
• Eisai Co., Ltd. Japanese pharmaceutical company with oncology portfolio (Lenvima) plus neurology/PAD areas. Comparable Japanese specialty pharma with overlapping oncology priorities and global commercial footprint.

Broad incumbents

• Takeda Pharmaceutical: Japan's largest pharmaceutical company with oncology alongside GI, rare diseases, and neuroscience. A larger, more diversified incumbent covering the same Japanese-pharma oncology category with broader portfolio.
• AstraZeneca: Global biopharmaceutical leader with extensive oncology franchise (Tagrisso, Imfinzi, Enhertu in partnership with Daiichi Sankyo). Co-promotion and clinical collaboration partner context for KRAS/EGFR targeted therapy development.
• Bristol-Myers Squibb: Global biopharmaceutical company with major oncology portfolio including checkpoint inhibitors and ADCs (Opdivo partnership with Ono). Broader incumbent with overlapping oncology priorities.
• Merck & Co. Active oncology drug discovery collaborator with Taiho via Astex Pharmaceuticals on KRAS G12C program (calderasib/KANDLELIT-007 with Keytruda). Comparable in oncology pipeline and ADC/biologics interest.

Regional players

• Kyowa Kirin: Japanese specialty pharmaceutical company focused on oncology, immunology, and rare diseases. Operates primarily in Japan/APAC comparable geographies with similar specialty-pharma positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@%E5%A4%A7%E9%B5%AC%E8%96%AC%E5%93%81%E3%83%98%E3%83%AB%E3%82%B9%E3%82%B1%E3%82%A2%E5%85%AC%E5%BC%8F
• Facebookfacebook.com/taihohealthcare
• LinkedInlinkedin.com/company/taiho-pharmaceutical-co.-ltd.-

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Taiho Pharmaceutical